Related references
Note: Only part of the references are listed.Central and peripheral nervous systems: master controllers in cancer metastasis
Ming Shi et al.
CANCER AND METASTASIS REVIEWS (2013)
Substance P Autocrine Signaling Contributes to Persistent HER2 Activation That Drives Malignant Progression and Drug Resistance in Breast Cancer
Susana Garcia-Recio et al.
CANCER RESEARCH (2013)
beta 2-AR-induced Her2 transactivation mediated by Erbin confers protection from apoptosis in cardiomyocytes
Ming Shi et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Beta-blocker usage and breast cancer survival: a nested case-control study within a UK Clinical Practice Research Datalink cohort
Chris R. Cardwell et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2013)
Use of β-Blockers, Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Risk of Breast Cancer Recurrence: A Danish Nationwide Prospective Cohort Study
Gitte Vrelits Sorensen et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Autonomic Nerve Development Contributes to Prostate Cancer Progression
Claire Magnon et al.
SCIENCE (2013)
Src activation by β-adrenoreceptors is a key switch for tumour metastasis
Guillermo N. Armaiz-Pena et al.
NATURE COMMUNICATIONS (2013)
Molecular Pathways: Beta-Adrenergic Signaling in Cancer
Steven W. Cole et al.
CLINICAL CANCER RESEARCH (2012)
Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
Celina Garcia-Garcia et al.
CLINICAL CANCER RESEARCH (2012)
Characterizing distress, the 6th vital sign, in an oncology pain clinic
A. Waller et al.
CURRENT ONCOLOGY (2012)
Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+Breast Cancer by Expanding the Cancer Stem Cell Population
Hasan Korkaya et al.
MOLECULAR CELL (2012)
Treatment of HER2-positive breast cancer: current status and future perspectives
Carlos L. Arteaga et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Mucin 1 enhances the tumor angiogenic response by activation of the AKT signaling pathway
J. K. Woo et al.
ONCOGENE (2012)
Multiple Analyses of G-Protein Coupled Receptor (GPCR) Expression in the Development of Gefitinib-Resistance in Transforming Non-Small-Cell Lung Cancer
Naoko Kuzumaki et al.
PLOS ONE (2012)
Improving Treatment of HER2-Positive Cancers: Opportunities and Challenges
Howard M. Stern
SCIENCE TRANSLATIONAL MEDICINE (2012)
Stimulation of Host Bone Marrow Stromal Cells by Sympathetic Nerves Promotes Breast Cancer Bone Metastasis in Mice
J. Preston Campbell et al.
PLOS BIOLOGY (2012)
Cancer induces inflammation and depressive-like behavior in the mouse: Modulation by social housing
Donald M. Lamkin et al.
BRAIN BEHAVIOR AND IMMUNITY (2011)
The beta 2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells
Ming Shi et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Identification of miRNomes in Human Liver and Hepatocellular Carcinoma Reveals miR-199a/b-3p as Therapeutic Target for Hepatocellular Carcinoma
Jin Hou et al.
CANCER CELL (2011)
Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer
Toru Mukohara
CANCER SCIENCE (2011)
Targeting GPCR-Mediated p70S6K Activity May Improve Head and Neck Cancer Response to Cetuximab
Neil E. Bhola et al.
CLINICAL CANCER RESEARCH (2011)
Signal transducer and activator of transcription 3-mediated regulation of miR-199a-5p links cardiomyocyte and endothelial cell function in the heart: a key role for ubiquitin-conjugating enzymes
Arash Haghikia et al.
EUROPEAN HEART JOURNAL (2011)
Up-regulation of miR-21 Mediates Resistance to Trastuzumab Therapy for Breast Cancer
Chang Gong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Expanding Our Therapeutic Options: Beta Blockers for Breast Cancer?
Patricia A. Ganz et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Beta Blockers and Breast Cancer Mortality: A Population-Based Study
Thomas I. Barron et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy
Phuong K. Morrow et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2-Overexpressing Locally Advanced Breast Cancers
Bhuvanesh Dave et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast Cancer
Amal Melhem-Bertrandt et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
GPCR/EGFR Cross Talk Is Conserved in Gonadal and Adrenal Steroidogenesis but Is Uniquely Regulated by Matrix Metalloproteinases 2 and 9 in the Ovary
Liliana Carbajal et al.
MOLECULAR ENDOCRINOLOGY (2011)
Overexpression of MUC1 Enhances Proangiogenic Activity of Non-Small-Cell Lung Cancer Cells Through Activation of Akt and Extracellular Signal-regulated Kinase Pathways
Mengying Yao et al.
LUNG (2011)
A stress response pathway regulates DNA damage through β2-adrenoreceptors and β-arrestin-1
Makoto R. Hara et al.
NATURE (2011)
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
Siyuan Zhang et al.
NATURE MEDICINE (2011)
TARGETED THERAPIES Using β-blockers to inhibit breast cancer progression
Desmond G. Powe et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
G protein-coupled receptors: novel targets for drug discovery in cancer
Rosamaria Lappano et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
MUC1-C Oncoprotein Promotes STAT3 Activation in an Autoinductive Regulatory Loop
Rehan Ahmad et al.
SCIENCE SIGNALING (2011)
Stress and breast cancer: from epidemiology to molecular biology
Lilia Antonova et al.
BREAST CANCER RESEARCH (2011)
Cytologically Proven Axillary Lymph Node Metastases Are Eradicated in Patients Receiving Preoperative Chemotherapy With Concurrent Trastuzumab for HER2-Positive Breast Cancer
Laura S. Dominici et al.
CANCER (2010)
Recombinant Human Erythropoietin Antagonizes Trastuzumab Treatment of Breast Cancer Cells via Jak2-Mediated Src Activation and PTEN Inactivation
Ke Liang et al.
CANCER CELL (2010)
MiR-199a-3p Regulates mTOR and c-Met to Influence the Doxorubicin Sensitivity of Human Hepatocarcinoma Cells
Francesca Fornari et al.
CANCER RESEARCH (2010)
The Sympathetic Nervous System Induces a Metastatic Switch in Primary Breast Cancer
Erica K. Sloan et al.
CANCER RESEARCH (2010)
Host Factors and Cancer Progression: Biobehavioral Signaling Pathways and Interventions
Susan K. Lutgendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
STAT3 Activation of miR-21 and miR-181b-1 via PTEN and CYLD Are Part of the Epigenetic Switch Linking Inflammation to Cancer
Dimitrios Iliopoulos et al.
MOLECULAR CELL (2010)
HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
Merel Gijsen et al.
PLOS BIOLOGY (2010)
Depression, social support, and beta-adrenergic transcription control in human ovarian cancer
Susan K. Lutgendorf et al.
BRAIN BEHAVIOR AND IMMUNITY (2009)
MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells
Shawn P. Fessler et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Protein Kinase A Activation Confers Resistance to Trastuzumab in Human Breast Cancer Cell Lines
Long Gu et al.
CLINICAL CANCER RESEARCH (2009)
Up-regulation of miR-21 by HER2/neu Signaling Promotes Cell Invasion
Tzu-Hsuan Huang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Neil L. Spector et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
ER2-dependent MMP-7 expression is mediated by activated STAT3
Guogang Yuan et al.
CELLULAR SIGNALLING (2008)
Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients
Susan K. Lutgendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of cancer and leukemia group B protocol 9840
Andrew D. Seidman et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification
Laurent Arnould et al.
CLINICAL CANCER RESEARCH (2007)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer
Fanyin Meng et al.
GASTROENTEROLOGY (2007)
CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
Francisco J. Esteva et al.
BREAST CANCER RESEARCH (2007)
Autoproteolysis coupled to protein folding in the SEA domain of the membrane-bound MUC1 mucin
B Macao et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2006)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Science and society - Stress-induced immune dysfunction: implications for health
R Glaser et al.
NATURE REVIEWS IMMUNOLOGY (2005)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata et al.
CANCER CELL (2004)
Share Paper
